This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson’s disease dementia


Larsson, Victoria, Aarsland, Dag, Ballard, Clive, Minthon, Lennart, Londos, Elisabet


International Journal Of Geriatric Psychiatry, Volume: 25, No.: 10, Pages.: 1030-1038

Year of Publication



Objective: Two common and characteristic sleep disturbances have been described in dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD); excessive daytime sleepiness and REM sleep behaviour disorder (RBD). This study is an analysis of a secondary outcome measure of a larger study already reported, aimed to determine whether memantine has an effect on the sleep disturbances in DLB and PDD patients.; Methods: Patients with DLB or PDD were included in a placebo-controlled, randomised controlled study of memantine (20 mg per day) for 24 weeks. The Stavanger Sleep Questionnaire and the Epworth Sleepiness Scale were used to evaluate the effect on sleep disturbances.; Results: Forty two patients started treatment; 20 with memantine and 22 with placebo. The primary analysis was the comparison of change between the two groups during a 24-week period, using the modified ITT population (last observation carried forward). At 24 weeks, patients treated with memantine were less physically active during sleep while patients in the placebo group worsened. Mean difference between the groups (0.5 [0.05-0.90]) was significant (p = 0.006). No significant change was observed in severity of excessive daytime sleepiness.; Conclusions: Memantine decreases probable REM sleep behaviour disorder in patients with DLB and PDD. Both diagnostic groups contributed equally to the outcome.; Copyright © 2010 John Wiley & Sons, Ltd.

Bibtex Citation

@article{Larsson_2010, doi = {10.1002/gps.2506}, url = {}, year = 2010, month = {apr}, publisher = {Wiley-Blackwell}, volume = {25}, number = {10}, pages = {1030--1038}, author = {Victoria Larsson and Dag Aarsland and Clive Ballard and Lennart Minthon and Elisabet Londos}, title = {The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson{textquotesingle}s disease dementia}, journal = {Int. J. Geriat. Psychiatry} }


aged, aged, 80 and over, disturbances, dopamine agents, drug effects, drug therapy, etiology, female, humans, lewy body disease, male, memantine, outcome assessment (health care), parkinson disease, psychology, questionnaires, sleep, sleep initiation and maintenance disorders, therapeutic use

Countries of Study


Types of Dementia

Lewy-Body, Parkinson’s Dementia

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime